ESMO: European Society for Medical Oncology

The latest news from ESMO
  1. Two new indications concern the treatment of paediatric patients with ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumour

  2. It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma

  3. New indication concerns the treatment of patients with diffuse large cell lymphoma and high-grade B-cell lymphoma

  4. Findings from an assessment of predictive value of RNF43 status in patients with BRAFV600E-mutated metastatic colorectal cancer

  5. New indication concerns treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy